Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.
Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O'Connor OA, Olshefski R, Smith SE, Huebner D, Levine PL, Grove LE, Gopal AK. Forero-Torres A, et al. Among authors: grove le. Leuk Lymphoma. 2015 Apr;56(4):1151-3. doi: 10.3109/10428194.2014.951843. Epub 2014 Oct 7. Leuk Lymphoma. 2015. PMID: 25110824 No abstract available.
Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.
Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz CH, Ramchandren R, Shustov AR, Tilly H, Trippett TM, Gibb A, Grove LE, Advani R. Illidge T, et al. Among authors: grove le. Leuk Lymphoma. 2015 Mar;56(3):703-10. doi: 10.3109/10428194.2014.930852. Epub 2015 Jan 21. Leuk Lymphoma. 2015. PMID: 24913507
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Han TH, Gopal AK, Ramchandren R, Goy A, Chen R, Matous JV, Cooper M, Grove LE, Alley SC, Lynch CM, O'Connor OA. Han TH, et al. Among authors: grove le. J Clin Pharmacol. 2013 Aug;53(8):866-77. doi: 10.1002/jcph.116. Epub 2013 Jun 10. J Clin Pharmacol. 2013. PMID: 23754575 Free PMC article. Clinical Trial.
A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
Ross HJ, Hart LL, Swanson PM, Rarick MU, Figlin RA, Jacobs AD, McCune DE, Rosenberg AH, Baron AD, Grove LE, Thorn MD, Miller DM, Drachman JG, Rudin CM. Ross HJ, et al. Among authors: grove le. Lung Cancer. 2006 Oct;54(1):69-77. doi: 10.1016/j.lungcan.2006.05.020. Epub 2006 Aug 28. Lung Cancer. 2006. PMID: 16934909 Free PMC article. Clinical Trial.
28 results